Orexigen Therapeutics, Inc. Investor Lawsuit against Directors filed

A lawsuit was filed by a current investor in NASDAQ-OREX shares against certain directors of Orexigen Therapeutics and current long-term NASDAQ-OREX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com
 
Jan. 27, 2014 - PRLog -- An investor who currently holds NASDAQ-OREX shares, filed a lawsuit against directors of Orexigen Therapeutics, Inc.  over alleged breaches of fiduciary duties.

Investors who are current long-term stockholder of shares of Orexigen Therapeutics, Inc. , have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com (mailto:mail@shareholdersfoundation.com) or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges that the defendants breached their fiduciary duties by  awarding themselves in excess of the 1.5million annual stock options allowed.

Orexigen Therapeutics, Inc. reported that its annual Total Revenue declined from $4.40 million in 2011 to $3.43 million in 2012 and that its respective Net Loss increased from $28.06 million to $90.09 million.

On December 13, 2013, NASDAQ-OREX shares closed at $5.58 per share.

Those who purchased shares of Orexigen Therapeutics, Inc. have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Contact
Shareholders Foundation, Inc.
+1-(858)-779-1554
mail@shareholdersfoundation.com
End
Source:
Email:***@shareholdersfoundation.com Email Verified
Tags:Nasdaq:orex, Lawsuit
Industry:Business, Finance
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share